10-Q: Journey Medical Corporation Reports First Quarter 2024 Results, Revenue Up 7% Amidst Strategic Shifts

Journey Medical Corporation's Q1 2024 results show a 7% increase in revenue, driven by key products, alongside increased R&D spending and reduced SG&A expenses.

Summary

• Journey Medical Corporation reported a net loss of $10.4 million for the first quarter of 2024, compared to a net loss of $10.1 million in the same period last year.
• Total revenue increased by 7% to $13.0 million, primarily driven by growth in sales of Qbrexza and Accutane.
• Research and development expenses significantly increased to $7.9 million, due to a $4.0 million FDA filing fee for DFD-29 and a $3.0 million milestone payment.
• Selling, general, and administrative expenses decreased by 37% to $8.4 million, reflecting cost management efforts.
• The company's cash and cash equivalents decreased to $24.1 million from $27.4 million at the end of 2023.
• The company issued 289,744 shares of common stock under its at-the-market offering, generating net proceeds of $1.5 million.
• A term loan facility with SWK Funding LLC provides up to $20.0 million, with $15.0 million drawn as of March 31, 2024.
• The company submitted a New Drug Application (NDA) for DFD-29, with a potential FDA approval expected in the second half of 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the ongoing losses, decreasing cash position, and the substantial doubt about the company's ability to continue as a going concern. However, there are some positive aspects such as revenue growth and cost management efforts.

Positives

• The company experienced a 7% increase in total revenue, driven by strong sales of Qbrexza and Accutane.
• Selling, general, and administrative expenses decreased by 37%, indicating successful cost management.
• The company successfully submitted an NDA for DFD-29, with a potential FDA approval expected in the second half of 2024.
• The company secured a term loan facility with SWK Funding LLC, providing access to up to $20.0 million in capital.

Negatives

• The company reported a net loss of $10.4 million for the quarter.
• Cash and cash equivalents decreased by $3.3 million during the quarter.
• Research and development expenses increased significantly due to the DFD-29 filing fee and milestone payment.
• The company has recurring losses and substantial doubt exists about its ability to continue as a going concern.

Risks

• The company's products are subject to time and cost-intensive regulation and clinical testing.
• A substantial portion of sales derive from products without patent protection, making them vulnerable to generic competition.
• The company operates in a heavily regulated industry, and future legislation could impact operations.
• The company's revenue is dependent on sales of dermatology products, and any setback could impair results.
• The company relies on third parties for several aspects of its operations.
• The company's success depends on the successful development and regulatory approval of DFD-29 and other product candidates.
• Clinical drug development is expensive, time-consuming, and uncertain.
• The company may need to raise additional capital, and there is no assurance that it will be available.
• Fortress Biotech controls a voting majority of the company's common stock, which could be detrimental to other shareholders.
• There is substantial doubt about the company's ability to continue as a going concern.

Future Outlook

The company expects potential FDA approval for DFD-29 in the second half of 2024 and may seek to raise additional capital through debt or equity financings to expand its product portfolio. The company's future performance is dependent on the successful commercialization of its products and the regulatory approval of DFD-29.

Management Comments

• The company is focused on marketing efforts for Qbrexza and Accutane.
• The company is managing expenses to improve operational efficiencies and reduce overall costs.
• The company is regularly evaluating market conditions and financing alternatives to enhance its capital structure.

Industry Context

The company operates in the competitive dermatology pharmaceutical market, facing competition from both branded and generic products. The successful development and approval of DFD-29 is critical for the company's future growth and profitability. The company's focus on cost management and strategic product marketing is aligned with industry trends.

Comparison to Industry Standards

• Journey Medical's revenue growth of 7% is moderate compared to some high-growth biotech companies, but is reasonable for a commercial-stage pharmaceutical company.
• The increase in R&D spending is typical for companies in the clinical trial phase, especially with a late-stage asset like DFD-29.
• The reduction in SG&A expenses is a positive sign, indicating a focus on operational efficiency, which is a common goal for companies in this sector.
• The company's reliance on a few key products for revenue is a risk, similar to other companies with a limited product portfolio.
• The company's cash burn rate is a concern, and the need for additional capital is a common challenge for companies in the biotech and pharmaceutical space.
• Compared to companies like Galderma or Almirall, which have a broader range of dermatology products, Journey Medical is more focused on a few key assets.
• The company's debt levels are moderate, but the interest rate on the SWK loan is relatively high, which is not uncommon for smaller companies with limited access to capital.

Related Party Transactions

• The company has a Shared Services Agreement with Fortress Biotech, where it reimburses Fortress for employee costs and other expenses.
• The due to related party liability at March 31, 2024 and December 31, 2023 was $0.2 million and $0.2 million, respectively, and primarily relate to reimbursable expenses incurred by Fortress on behalf of the Company.
• Fortress Biotech owns 50.43% of all classes of the company's outstanding common stock.

Stakeholder Impact

• Shareholders are impacted by the company's net loss and the substantial doubt about its ability to continue as a going concern.
• Employees are impacted by the company's cost management efforts and potential changes in operations.
• Customers are impacted by the company's product availability and marketing strategies.
• Suppliers and creditors are impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to focus on the commercialization of its existing products.
• The company will await the FDA's decision on the DFD-29 NDA.
• The company will evaluate market conditions and financing alternatives to enhance its capital structure.
• The company will monitor the performance of its products and adjust its marketing strategies as needed.

Key Dates

Keywords

dermatology, pharmaceuticals, FDA, DFD-29, Qbrexza, Accutane, clinical trials, revenue, research and development, financial results